JUBLPHARMA.BOJUBLPHARMA.BOBSE
Loading
EBITDA Over TimeStable
Percentile Rank43
3Y CAGR-0.6%
5Y CAGR-7.5%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
-0.6%/yr
vs -7.6%/yr prior
5Y CAGR
-7.5%/yr
Recent acceleration
Acceleration
+7.0pp
Accelerating
Percentile
P43
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
2 yr
Consecutive growthStable
PeriodValueYoY Change
2025$10.48B+32.1%
2024$7.93B+22.7%
2023$6.46B-39.4%
2022$10.66B-27.3%
2021$14.68B-5.2%
2020$15.48B-7.0%
2019$16.64B+13.7%
2018$14.64B+12.2%
2017$13.05B+11.3%
2016$11.72B-